Application and mechanistic research of novel therapeutic strategies in cisplatin-resistant small cell lung cancer.

Ann Med · 2026 · PMC13011102 · PMID 41869709

Europe PMC DOI

hedged sentence

0.1723

closest p · 3.4× alpha

0.1723

boldest claim

The sentences

did not reach statistical significancep = 0.1723not close (p > 0.1)

In contrast, the anlotinib + EC arm showed a median OS of 13.3 months versus 11.9 months for EC alone, but this improvement did not reach statistical significance (HR = 0.86; p = 0.1723).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.